On June 18, WuXi Biologics rose 3.35% in regular trading, trading at HKD 30.8/share, with turnover of approximately HKD 160 million. The rally was driven by a surge of buyback activity across the pharmaceutical sector, signaling that industry leaders view current valuations as having bottomed.

On the news front, WuXi AppTec announced the completion of a HKD 2.5 billion H-share buyback program designated for employee incentives, while China Grand Pharmaceutical disclosed plans to repurchase up to HKD 2 billion in shares over the next 12 months, citing that its stock price has been severely undervalued. Data shows that 51 Hong Kong-listed pharma companies have executed buybacks this year, with cumulative repurchase amounts exceeding HKD 60 billion. WuXi Biologics itself repurchased approximately HKD 100 million worth of shares on both June 11 and June 12.

Within the Life Sciences Tools and Services sector, the broader group traded higher. WUXI APPTEC rose 3.59%, INSILICO gained 5.94%, GENSCRIPT BIO climbed 2.93%, XTALPI added 1.67%, and WUXI XDC advanced 1.57%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)